Lupus Nephritis Market Expected to Gain Momentum Through 2034, According to DelveInsight

The Lupus Nephritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lupus Nephritis pipeline products will significantly revolutionize the Lupus Nephritis market dynamics.

DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Lupus Nephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lupus Nephritis Market Forecast
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Lupus Nephritis Market Report:
• The Lupus Nephritis market size was estimated at USD 1,958 million in 2025 and is expected to expand at a notable CAGR of 8.5% over the forecast period from 2020 to 2034.
• In March 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of lupus nephritis. This acceptance is supported by positive findings from the Phase III REGENCY trial, which demonstrated enhanced complete renal response (CRR) when Gazyva/Gazyvaro was added to standard therapy, compared to standard treatment alone. The FDA is expected to deliver a decision on the application by October 2025.
• In February 2025, the FDA approved Allogene Therapeutics' investigational new drug (IND) application for ALLO-329, an allogeneic CAR-T cell therapy. The Phase 1 RESOLUTION trial is expected to commence in mid-2025, targeting autoimmune diseases such as systemic lupus erythematosus (SLE), lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.
• In November 2024, Adicet Bio reported that the initial patient with lupus nephritis (LN) has received a dose in its Phase I clinical trial assessing ADI-001 for autoimmune disorders.
• In November 2024, Kyverna Therapeutics revealed plans to share updated clinical data from lupus nephritis (LN) patients treated with KYV-101 in its ongoing KYSA-1 and KYSA-3 Phase I/II trials, as well as through named patient treatments.
• DelveInsight's estimates indicate that the US held the largest share of the Lupus Nephritis market in 2024. Within the EU4 and the UK, Spain accounted for the highest Lupus Nephritis drug market share, followed by the UK, whereas France recorded the lowest share in 2024.
• In Japan, the Lupus Nephritis market was valued at approximately USD 49 million in 2024 and is projected to grow over the forecast period from 2025 to 2034.
• The epidemiology section presents data and insights on Lupus Nephritis across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• In 2024, the number of diagnosed prevalent cases in the US was approximately 218,000, with expectations of growth throughout the forecast period.
• In 2024, the EU4 and the UK had nearly 130,000 diagnosed prevalent cases of Lupus Nephritis. The US represented the largest share of the Lupus Nephritis population, accounting for about 60% of the 7MM in 2024.
• Within the EU4 and the UK, Spain recorded the highest number of diagnosed cases, followed by the UK, while France had the fewest cases. In the US, the age distribution of diagnosed cases in 2024 showed approximately 7% in individuals under 18 years and around 93% in those aged 18 years and older.
• In 2024, Class IV was the most common form of Lupus Nephritis in Japan, with approximately 18,000 diagnosed cases, indicating a persistently high disease burden. Class III was the second most prevalent subtype, with around 6,800 cases reported.
• Key Lupus Nephritis Companies: Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GlaxoSmithKline, Roche, Novartis, Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
• Key Lupus Nephritis Therapies: LUPKYNIS (voclosporin), BENLYSTA (belimumab), GAZYVA/GAZYVARO (obinutuzumab), Ianalumab (VAY736), IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others

Lupus Nephritis Overview
Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease. It specifically refers to inflammation of the kidneys caused by the immune system mistakenly attacking the kidney tissues.

Get a Free sample for the Lupus Nephritis Market Report:
https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lupus Nephritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Lupus Nephritis Epidemiology Segmentation:
The Lupus Nephritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Lupus Nephritis
• Prevalent Cases of Lupus Nephritis by severity
• Gender-specific Prevalence of Lupus Nephritis
• Diagnosed Cases of Episodic and Chronic Lupus Nephritis

Download the report to understand which factors are driving Lupus Nephritis epidemiology trends @ Lupus Nephritis Epidemiological Insights
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lupus Nephritis Market
The dynamics of the Lupus Nephritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Obinutuzumab, Myfortic, and others during the forecasted period 2020-2034.

Lupus Nephritis Therapies and Key Companies
• LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceuticals
• BENLYSTA (belimumab): GlaxoSmithKline
• GAZYVA/GAZYVARO (obinutuzumab): Roche
• Ianalumab (VAY736): Novartis
• Secukinumab: Novartis
• Obinutuzumab: Roche
• GAZYVA: Roche
• Saphnelo (Anifrolumab): AstraZeneca
• Iscalimab: Novartis
• IBL-101: Inflection Biosciences
• RG 6107: Roche
• Itolizumab: Equillium
• Zanubrutinib: BeiGene
• Guselkumab: Janssen Research & Development
• Daxdilimab: Horizon Therapeutics
• Cosentyx: Novartis
• Ravulizumab: Alexion Pharmaceuticals
• Anifrolumab: AstraZeneca

To know more about Lupus Nephritis treatment, visit @ Lupus Nephritis Medications
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lupus Nephritis Market Drivers
• Rising prevalence of lupus and autoimmune disorders leading to increased cases of lupus nephritis.
• Advancements in diagnostic tools allowing earlier and more accurate detection.
• Introduction of novel therapies and biologics improving patient outcomes.
• Growing awareness among physicians and patients about lupus nephritis management.
• Expansion of healthcare infrastructure and access to treatment in developed and emerging markets.
• Increased R&D investment by pharmaceutical companies driving pipeline innovations.

Lupus Nephritis Market Barriers
• High treatment costs limiting accessibility, especially in emerging markets.
• Limited availability of specialized therapies in certain regions.
• Side effects and long-term complications associated with existing treatment options.
• Delayed diagnosis or misdiagnosis due to complex symptoms.
• Regulatory challenges and slow approval processes for new drugs.
• Patient non-compliance with long-term treatment regimens.

Scope of the Lupus Nephritis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Lupus Nephritis Companies: Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GlaxoSmithKline, Roche, Novartis, Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
• Key Lupus Nephritis Therapies: LUPKYNIS (voclosporin), BENLYSTA (belimumab), GAZYVA/GAZYVARO (obinutuzumab), Ianalumab (VAY736), IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
• Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
• Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Lupus Nephritis Unmet Needs, KOL's views, Analyst's views, Lupus Nephritis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.